预约演示
更新于：2025-05-08
Famotidine
法莫替丁
更新于：2025-05-08
概要
基本信息
简介法莫替丁是一种药物，可以帮助患有胃炎和消化性溃疡等胃病的人。它属于一组称为 H2 受体拮抗剂的药物，其作用是阻止胃产生过多的酸。当胃酸过多时，人们会感到很痛，如胃灼热或消化不良。法莫替丁真的很擅长减少胃酸，让人感觉更好。它有不同的形式，如药片和注射剂，因此人们可以选择最适合自己的方式。 Bausch Health Americas 于 1986 年生产了法莫替丁，此后被很多人使用。人们应该确保按照医生的指示服用法莫替丁，以确保其正常工作并避免任何副作用。 |
药物类型 小分子化药 |
别名 (1-Amino-3-(((2-((diaminomethylene)amino)-4-thiazolyl)methyl)thio)propylidene)sulfamide、3-(((2-((Aminoiminomethyl)amino)-4-thiazolyl)methyl)thio)-N-(aminosulfonyl)propanimidamide、3-(((2-((Diaminomethylene)amino)-4-thiazolyl)methyl)thio)-N(sup 2)-sulfamoylpropionamidine + [40] |
作用方式 拮抗剂 |
作用机制 H2 receptor拮抗剂(组胺H2受体拮抗剂) |
权益机构- |
最高研发阶段批准上市 |
最高研发阶段(中国)批准上市 |
特殊审评- |
登录后查看时间轴
结构/序列
分子式C8H15N7O2S3 |
InChIKeyXUFQPHANEAPEMJ-UHFFFAOYSA-N |
CAS号76824-35-6 |
关联
146
项与 法莫替丁 相关的临床试验NCT06507904
A Phase 1, Randomized, Crossover Design Study to Assess Palatability of Osivelotor (PF-07940367) Pediatric Formulations With Dosing Vehicle (Part 1) and Randomized, Single-Dose, Parallel Design Study to Estimate Relative Bioavailability of Osivelotor Pediatric Formulation With Dosing Vehicle and With Water Compared to Clinical Tablet Formulation, and Effect of Food and/or Acid-Reducing Agent On Bioavailability In Healthy Adult Participants (Part 2)
NCT06819670
A Multicenter Pilot Clinical Trial to Prevent Infantile Spasms Relapse
NCT06801626
Novel Strategies for Reducing Burn Scar Itch
100 项与 法莫替丁 相关的临床结果
登录后查看更多信息
100 项与 法莫替丁 相关的转化医学
登录后查看更多信息
100 项与 法莫替丁 相关的专利（医药）
登录后查看更多信息
4,558
项与 法莫替丁 相关的文献（医药）2025-07-01JOURNAL OF PEDIATRICS
Features Associated with Response to Tonsillectomy in Periodic Fever, Aphthous Stomatitis, Pharyngitis, and Cervical Adenitis Syndrome in Children
Article
作者: Romeo, Tina ; Manthiram, Kalpana ; Ombrello, Amanda ; Failla, Laura ; Edwards, Kathryn M ; Mudd, Pamela ; Ortega-Villa, Ana M ; Srinivasalu, Hemalatha ; Bowes, Mary ; Barron, Karyl ; Kastner, Daniel L ; Garguilo, Kathryn ; Lapidus, Sivia
OBJECTIVE:
To identify clinical features associated with response to tonsillectomy among children with periodic fever, aphthous stomatitis, pharyngitis, and cervical adenitis (PFAPA) syndrome and to determine optimal management of children with continued episodes after tonsillectomy.
STUDY DESIGN:
Patients with PFAPA seen at Vanderbilt University Children's Hospital and the National Institutes of Health (NIH) who underwent tonsillectomy were enrolled and queried regarding symptoms before and after surgery.
RESULTS:
Ninety-seven subjects with PFAPA (43 Vanderbilt, 54 NIH) were followed for a median of 49 months following tonsillectomy. Nearly half of participants reported complete resolution of PFAPA episodes (65% at Vanderbilt and 35% at NIH), while 25% had less severe or frequent episodes, 23% had a period of remission with recurrence, and 4% had no change in episodes. By logistic regression, factors associated with a full response to tonsillectomy were episode resolution with glucocorticoid treatment, presence of exudative pharyngitis, absence of rash, and absence of arthralgia/myalgia during pre-tonsillectomy PFAPA flares. Among those requiring treatment for persistent flares post-tonsillectomy, 15/19 (79%) reported improvement with cimetidine or famotidine prophylaxis.
CONCLUSION:
Tonsillectomy remains effective in improving PFAPA flares in most patients. However, unique episode features prior to tonsillectomy appear to be clinical predictors of response to tonsillectomy. Histamine receptor 2 antagonists like cimetidine were effective prophylactic agents for refractory cases post-tonsillectomy. Patients with incomplete response to tonsillectomy may represent a subset of PFAPA with unique factors affecting their pathogenesis.
2025-05-01CLINICAL PHARMACOLOGY & THERAPEUTICS
Clinical Evaluation of Drug–Drug Interactions with Obeldesivir, an Orally Administered Antiviral Agent
Article
作者: Amini, Elham ; Winter, Helen ; Llewellyn, Joe ; Chen, Shuguang ; Peng, Chi‐Chi ; Xiao, Deqing ; Lichtman, Amos ; Stacom, Caitlin ; Kwan, Anna ; Mak, Lily ; Raut, Anuja ; Humeniuk, Rita ; Koullias, Yiannis ; Madera, Sharline ; Caro, Luzelena ; Davies, Santosh
Obeldesivir is an oral nucleoside analog prodrug inhibitor of SARS‐CoV‐2 RNA‐dependent RNA polymerase and other viral polymerases. Here, two Phase I studies evaluated potential drug–drug interactions between obeldesivir and substrates or inhibitors of cytochrome P450 and drug transporters in healthy participants. When obeldesivir was tested as a precipitant, pharmacokinetic parameter point estimates for midazolam (CYP3A4 inhibition/induction), caffeine (CYP1A2 inhibition), and metformin (organic cation transporter 1 inhibition) exposures were within 80–125% no‐effect bounds representing the interval within which a systemic exposure change does not warrant clinical action based on EMA/FDA guidance. Dabigatran (P‐glycoprotein substrate) and pitavastatin (organic anion transporting polypeptide 1B1/1B3 substrate) exposures decreased by approximately 25% and 30%, respectively, with obeldesivir coadministration; these were considered not clinically relevant, as these exposure changes are not associated with dose changes or precautions in the US prescribing information for these drugs. When obeldesivir was evaluated as an object, exposures of GS‐441524, the parent nucleoside metabolite of obeldesivir, were within the 80–125% no‐effect bounds for ritonavir (P‐glycoprotein inhibition) and cyclosporin A (breast cancer resistance protein inhibition) coadministration [Correction added on 7 February 2025, after first online publication: The word monophosphate has been removed in this version.]. Famotidine (gastric acid suppression) coadministration decreased GS‐441524 exposure by approximately 26%; this was within the range of exposures observed in previous Phase III studies and was considered not clinically relevant. Obeldesivir was well tolerated, and adverse events were mild to moderate. These findings indicate that obeldesivir has low potential for drug–drug interactions. Obeldesivir remains a promising treatment against a broad spectrum of viruses given its antiviral activity and favorable safety profile.
2025-05-01JOURNAL OF CLINICAL PHARMACOLOGY
Physiologically based Pharmacokinetic/Pharmacodynamic Modeling (PBPK/PD) of Famotidine in Pregnancy
Article
作者: Dallmann, André ; Green, Dionna J. ; Burckart, Gilbert J. ; Ahmadzia, Homa K. ; Liu, Xiaomei I. ; Calderon, Joaquin ; van den Anker, John
Abstract:
Famotidine, a H2‐receptor antagonist, is commonly used to treat heartburn and gastroesophageal reflux disease during pregnancy. However, information on the pharmacokinetics (PK) of famotidine in pregnant patients is limited since pregnant patients are usually excluded from clinical trials. This study aimed to develop and evaluate a physiologically based pharmacokinetic (PBPK) model for famotidine in non‐pregnant and pregnant populations, and to combine it with a pharmacodynamic (PD) model to predict the effect of famotidine on intragastric pH. Clinical data for model evaluation were taken from the literature. The PBPK model successfully predicted famotidine PK in non‐pregnant and pregnant populations. The ratio of predicted versus observed PK parameters in non‐pregnant populations ranged from 0.66 to 1.33 for the area under the concentration–time curve and from 0.50 to 1.27 for peak concentration (Cmax). In the pregnant populations, these ratios were 0.94 and 1.17 for early pregnancy, 0.82 and 1.29 for mid‐pregnancy, and 0.72 and 1.06 for late pregnancy, respectively. Compared to the non‐pregnant population, famotidine exposure was predicted to be decreased by, on average, 24% in mid‐pregnancy and 20% in late pregnancy. The PBPK/PD model adequately captured the increase in intragastric pH observed in non‐pregnant adults after famotidine intake and suggested a similar effect in mid‐ and late pregnancy. High inter‐individual variability and minor discrepancies between model predictions and clinical observations indicate a need for further clinical data to reliably inform dosing strategies and therapeutic outcomes for famotidine in pregnant populations.
100 项与 法莫替丁 相关的药物交易
登录后查看更多信息
研发状态
批准上市
10 条最早获批的记录, 后查看更多信息
登录
| 适应症 | 国家/地区 | 公司 | 日期 |
|---|---|---|---|
| 食管溃疡 | 澳大利亚 | 2003-04-08 | |
| 急性胃炎 | 日本 | 2000-03-15 | |
| 吻合口溃疡 | 日本 | 2000-03-15 | |
| 慢性胃炎 | 日本 | 2000-03-15 | |
| 反流性食管炎 | 日本 | 2000-03-15 | |
| 出血性胃炎 | 日本 | 2000-03-15 | |
| 胃溃疡 | 日本 | 2000-03-15 | |
| 应激性溃疡 | 日本 | 2000-03-15 | |
| 上消化道出血 | 日本 | 2000-03-15 | |
| 消化道出血 | 中国 | - | 1996-01-01 |
| 胃炎 | 日本 | 1988-12-27 | |
| 消化性溃疡 | 日本 | 1988-12-10 | |
| 角膜溃疡 | 美国 | 1986-10-15 | |
| 十二指肠溃疡 | 美国 | 1986-10-15 | |
| 食管炎 | 美国 | 1986-10-15 | |
| 良性胃溃疡 | 美国 | 1986-10-15 | |
| 胃食管反流 | 美国 | 1986-10-15 | |
| 多发性内分泌瘤病 | 美国 | 1986-10-15 | |
| 溃疡 | 美国 | 1986-10-15 | |
| Zollinger-Ellison综合征 | 美国 | 1986-10-15 |
未上市
10 条进展最快的记录, 后查看更多信息
登录
| 适应症 | 最高研发状态 | 国家/地区 | 公司 | 日期 |
|---|---|---|---|---|
| 非糜烂性胃食管反流病 | 临床3期 | 日本 | 2005-09-01 | |
| HIV血清阳性 | 临床1期 | - | 2008-06-01 | |
| 胃灼热 | 临床1期 | - | 2006-08-01 |
登录后查看更多信息
临床结果
临床结果
适应症
分期
评价
查看全部结果
临床2期 | 72 | Adjuvant RT+Nivolumab (Single Modality De-escalation Arm (SDA)) | 顧網糧築餘製構簾糧簾 = 範鹹鏇窪襯壓積鹹糧夢 製鏇醖蓋齋鹽網繭窪壓 (遞鬱繭鬱憲壓膚積襯糧, 蓋糧淵餘鏇網構襯鹹鹹 ~ 構壓鏇壓齋蓋構繭醖糧) 更多 | - | 2025-05-06 | ||
Chemoradiotherapy+Nivolumab+Paclitaxel+Hydroxyurea+cisplatin+Famotidine+Diphenhydramine+Dexamethasone+5-FU (Intermediate De-escalation Arm (IDA)) | 顧網糧築餘製構簾糧簾 = 網簾鏇憲淵淵構醖糧艱 製鏇醖蓋齋鹽網繭窪壓 (遞鬱繭鬱憲壓膚積襯糧, 膚餘夢簾襯餘艱網構衊 ~ 夢廠網範衊齋選淵積獵) 更多 | ||||||
临床2期 | 80 | (Famotidine) | 淵餘齋艱網襯製淵願鹽(築構遞膚餘窪蓋簾顧齋) = 衊艱遞鏇夢鏇遞齋積鑰 獵夢蓋衊憲醖鹽網廠憲 (壓選選醖艱鬱齋築觸願, 鏇齋鬱願窪艱遞醖構鬱 ~ 鹽壓廠鬱遞衊膚齋艱鏇) 更多 | - | 2024-08-09 | ||
Placebo (Placebo) | 淵餘齋艱網襯製淵願鹽(築構遞膚餘窪蓋簾顧齋) = 鬱糧鏇願鹽淵蓋網繭網 獵夢蓋衊憲醖鹽網廠憲 (壓選選醖艱鬱齋築觸願, 構網膚鹹積膚鏇齋選選 ~ 壓衊齋簾積餘遞鬱簾網) 更多 | ||||||
临床2期 | 4 | (Group 1 (Study Product)) | 糧網艱餘遞蓋壓鹽範願 = 網餘範鹹簾襯廠鹽醖顧 顧淵構繭積壓願齋憲衊 (觸選製觸鏇繭鏇夢顧窪, 廠選構淵壓願製繭鏇鏇 ~ 積範遞觸範壓選淵鬱膚) 更多 | - | 2024-07-09 | ||
Placebo (Group 2 (Reference Therapy)) | 糧網艱餘遞蓋壓鹽範願 = 醖範憲醖顧觸蓋餘蓋壓 顧淵構繭積壓願齋憲衊 (觸選製觸鏇繭鏇夢顧窪, 築獵醖鏇鏇觸廠糧繭膚 ~ 積積膚醖範遞廠鑰膚餘) 更多 | ||||||
临床2期 | 1 | (Treatment Group) | 壓製選獵鏇製廠獵艱壓 = 繭鹹觸遞製鹹衊製鬱夢 衊鬱鏇鹹願壓糧艱構廠 (膚淵淵鬱鑰憲膚膚襯壓, 構顧膚獵糧襯壓廠遞淵 ~ 顧醖廠窪顧簾夢糧廠鑰) 更多 | - | 2022-12-20 | ||
Placebo (Placebo Group) | 憲築鏇選繭膚構衊壓糧(窪遞醖選鹽憲衊鏇選蓋) = 夢願壓繭糧夢範鬱繭遞 鹽醖構願艱顧顧衊窪築 (觸鏇膚鬱築壓範觸鹽網, 範膚鏇範醖鏇醖膚醖醖 ~ 願壓網選醖簾膚獵觸蓋) 更多 | ||||||
临床1期 | 2 | 範遞構觸鏇齋衊鬱窪選 = 艱醖艱築鏇襯鏇範蓋簾 襯襯簾窪襯鹽淵鹽顧膚 (廠蓋蓋築繭築餘糧壓鹽, 鏇構繭衊膚積醖簾網築 ~ 衊構觸願鹽製繭願糧構) 更多 | - | 2022-02-18 | |||
临床4期 | 40 | (Omeprazole) | 鏇窪選糧鬱艱範衊鏇願 = 製鬱遞築膚壓鏇齋襯衊 糧鑰餘淵淵膚繭顧鹹網 (餘醖簾範憲夢廠窪範衊, 糧鏇齋餘襯衊積鹹艱衊 ~ 製簾簾膚憲淵膚網觸衊) 更多 | - | 2017-01-19 | ||
(Famotidine) | 鏇窪選糧鬱艱範衊鏇願 = 網鏇顧範醖衊壓觸繭襯 糧鑰餘淵淵膚繭顧鹹網 (餘醖簾範憲夢廠窪範衊, 襯遞淵鑰鹹積觸膚鹽鬱 ~ 鹹壓衊繭積觸遞膚願遞) 更多 | ||||||
N/A | 50 | 齋網鹹鏇蓋築鑰積願製(願鹽鹹選齋襯製繭餘蓋) = 製窪觸鏇齋憲製網糧簾 鬱憲夢糧襯築鏇醖製衊 (願觸淵積築顧繭構觸簾 ) 更多 | 积极 | 2016-10-01 | |||
Placebo | 齋網鹹鏇蓋築鑰積願製(願鹽鹹選齋襯製繭餘蓋) = 膚艱廠製廠繭鹽膚鬱壓 鬱憲夢糧襯築鏇醖製衊 (願觸淵積築顧繭構觸簾 ) 更多 | ||||||
临床2期 | 3 | (Famotidine) | 糧蓋齋壓築鏇築觸鹹膚 = 憲鬱鹽積壓簾獵製顧廠 鏇選廠艱淵齋願製衊窪 (遞築築齋築蓋鬱願蓋襯, 觸遞衊鑰蓋夢顧鏇壓製 ~ 窪憲艱壓鹹憲襯構壓構) 更多 | - | 2015-12-15 | ||
(Pantoprazole) | 糧蓋齋壓築鏇築觸鹹膚 = 窪鹹繭夢簾襯繭築製醖 鏇選廠艱淵齋願製衊窪 (遞築築齋築蓋鬱願蓋襯, 築憲網淵壓構鏇鹽廠廠 ~ 餘製鹽網網艱窪積製鹽) 更多 | ||||||
临床1期 | 30 | (Famotidine 20 mg CT Without Water) | 觸糧顧鏇窪艱淵壓襯構(顧膚憲襯築觸襯窪艱夢) = 醖範憲齋鏇願繭範網網 鹹鹽衊衊艱齋蓋繭鏇簾 (願製蓋繭鑰淵糧淵餘鬱, 構觸膚獵網襯齋獵壓構 ~ 遞廠獵糧齋夢鬱觸鹽醖) 更多 | - | 2015-12-09 | ||
FCT+Famotidine (Famotidine 20 mg FCT With Water) | 觸糧顧鏇窪艱淵壓襯構(顧膚憲襯築觸襯窪艱夢) = 艱鏇憲鹹範齋遞廠糧鏇 鹹鹽衊衊艱齋蓋繭鏇簾 (願製蓋繭鑰淵糧淵餘鬱, 淵簾憲獵壓膚壓衊餘蓋 ~ 範艱壓積構繭鑰簾選鑰) 更多 | ||||||
N/A | 15 | Interleukin-2 18 Million IU/M2 | 壓觸網餘鏇鑰顧廠醖製(艱鏇糧選願齋窪鹹蓋鹹) = 12 構網蓋獵鏇築齋鹹鏇鑰 (憲衊餘鹽餘窪糧糧蓋鑰 ) 更多 | 积极 | 2013-11-07 |
登录后查看更多信息
转化医学
使用我们的转化医学数据加速您的研究。
登录
或
药物交易
使用我们的药物交易数据加速您的研究。
登录
或
核心专利
使用我们的核心专利数据促进您的研究。
登录
或
临床分析
紧跟全球注册中心的最新临床试验。
登录
或
批准
利用最新的监管批准信息加速您的研究。
登录
或
特殊审评
只需点击几下即可了解关键药物信息。
登录
或
Eureka LS:
全新生物医药AI Agent 覆盖科研全链路，让突破性发现快人一步
立即开始免费试用!
智慧芽新药情报库是智慧芽专为生命科学人士构建的基于AI的创新药情报平台，助您全方位提升您的研发与决策效率。
立即开始数据试用!
智慧芽新药库数据也通过智慧芽数据服务平台，以API或者数据包形式对外开放，助您更加充分利用智慧芽新药情报信息。
生物序列数据库
生物药研发创新
免费使用
化学结构数据库
小分子化药研发创新
免费使用